
Olivier Huillard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2281399/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Redifferentiating Effect of Larotrectinib in <i>NTRK</i> -Rearranged Advanced Radioactive-lodine Refractory Thyroid Cancer. Thyroid, 2022, 32, 594-598.	4.5	19
2	Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 612-624.	10.7	66
3	Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab. Clinical Genitourinary Cancer, 2022, 20, e362-e368.	1.9	7
4	Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. Cancers, 2022, 14, 3214.	3.7	2
5	Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/i.eururo.2020.10.006. European Urology. 2021. 79. e112.	1.9	2
6	Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. Clinical Medicine, 2021, 21, e552-e555.	1.9	1
7	Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer. Thyroid, 2021, 31, 1603-1604.	4.5	10
8	Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19, 554-562.	1.9	6
9	Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. Clinical Genitourinary Cancer, 2020, 18, 155-160.	1.9	13
10	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. Clinical Genitourinary Cancer, 2020, 18, 295-303.e3.	1.9	12
11	Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer. New England Journal of Medicine, 2020, 383, 1686-1687.	27.0	43
12	Management of Cancer Cachexia: ASCO Guideline—Time to Address the Elephant in the Room. Journal of Clinical Oncology, 2020, 38, 3819-3819.	1.6	1
13	Cancer treatment during the coronavirus disease 2019 pandemic: DoÂnot postpone but decide wisely. European Journal of Cancer, 2020, 135, 51.	2.8	3
14	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, managementÂand outcome. European Journal of Cancer, 2020, 129, 117-122.	2.8	12
15	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. European Journal of Cancer, 2020, 136, 76-83.	2.8	19
16	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 2020, 12, 931.	3.7	12
17	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. Thyroid, 2019, 29, 1820-1827.	4.5	15
18	RE: Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review. Journal of the National Cancer Institute, 2019, 111, 335-336.	6.3	1

OLIVIER HUILLARD

#	Article	IF	CITATIONS
19	Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study Journal of Clinical Oncology, 2019, 37, 582-582.	1.6	4
20	Resting energy expenditure in the risk assessment of anticancer treatments. Clinical Nutrition, 2018, 37, 558-565.	5.0	25
21	Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. Thyroid, 2018, 28, 72-78.	4.5	89
22	Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Fundamental and Clinical Pharmacology, 2018, 32, 98-107.	1.9	22
23	Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience. Frontiers in Surgery, 2018, 5, 58.	1.4	16
24	Mental disorders associated with recent cancer diagnosis: Results from a nationally representative survey. European Journal of Cancer, 2018, 105, 10-18.	2.8	23
25	Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registryâ€based study. Cancer, 2018, 124, 3044-3051.	4.1	17
26	A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. Pharmacological Research, 2018, 136, 56-61.	7.1	11
27	Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, e493-e495.	1.9	2
28	Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Investigational New Drugs, 2017, 35, 436-441.	2.6	73
29	A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1058, 102-107.	2.3	12
30	Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy ,. American Journal of Clinical Nutrition, 2017, 105, 1139-1147.	4.7	74
31	Clinical Diagnosis of Mental Disorders Before Cancer Diagnosis. JAMA Oncology, 2017, 3, 565.	7.1	5
32	Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. European Journal of Cancer, 2017, 72, 54-61.	2.8	54
33	Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75Âyears-old. Investigational New Drugs, 2017, 35, 242-246.	2.6	20
34	Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer. Journal of the Endocrine Society, 2017, 1, 285-287.	0.2	20
35	Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2801-2811.	4.3	54
36	Relationship between sarcopenia and dose-limiting toxicity (DLT) of sorafenib (SOR) in patients (pts) with advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) in the phase III DECISION trial Journal of Clinical Oncology, 2017, 35, e17594-e17594.	1.6	0

OLIVIER HUILLARD

#	Article	IF	CITATIONS
37	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) Journal of Clinical Oncology, 2017, 35, e16022-e16022.	1.6	0
38	Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1433-1444.	3.3	19
39	Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer. Lancet Oncology, The, 2016, 17, e468.	10.7	3
40	A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma. International Journal of Gynecological Cancer, 2016, 26, 1196-1200.	2.5	7
41	Angiotensin System Inhibitors in Renal Cell Carcinoma—Letter. Clinical Cancer Research, 2016, 22, 524-524.	7.0	2
42	Goals and aggressiveness of care in metastatic lung cancer Journal of Clinical Oncology, 2016, 34, 10026-10026.	1.6	1
43	Aggressiveness of care at the end of life in patients with localized and advanced bladder cancer Journal of Clinical Oncology, 2016, 34, 10029-10029.	1.6	Ο
44	Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decisionâ€Making. Oncologist, 2015, 20, e26.	3.7	9
45	Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib—Letter. Clinical Cancer Research, 2015, 21, 5639-5639.	7.0	3
46	Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. Expert Opinion on Investigational Drugs, 2015, 24, 673-687.	4.1	7
47	Sorafenib for patients with differentiated thyroid cancer. Lancet, The, 2015, 385, 227.	13.7	5
48	A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 989, 86-90.	2.3	15
49	Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 785-794.	3.3	31
50	Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?. Journal of Clinical Oncology, 2015, 33, 2484-2485.	1.6	6
51	Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Cancer Chemotherapy and Pharmacology, 2015, 76, 1033-1039.	2.3	7
52	Relationship between abiraterone plasma concentration and PSA response in metastatic castration resistant prostate cancer patients Journal of Clinical Oncology, 2015, 33, 5041-5041.	1.6	0
53	Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib?. Journal of Clinical Oncology, 2015, 33, 9537-9537.	1.6	0
54	Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept Journal of Clinical Oncology, 2015, 33, 2572-2572.	1.6	0

OLIVIER HUILLARD

#	Article	IF	CITATIONS
55	How should we manage bevacizumab toxicity in lung cancer patients?. Lung Cancer Management, 2014, 3, 355-363.	1.5	0
56	Sorafenib in Thyroid Cancer Patients: Learning From Toxicity. Oncologist, 2014, 19, e3.	3.7	5
57	Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Expert Opinion on Drug Safety, 2014, 13, 663-673.	2.4	15
58	Multidisciplinary risk assessment to reveal cancer treatments in complex cancer patients Journal of Clinical Oncology, 2014, 32, 170-170.	1.6	1
59	Multidisciplinary risk assessment to reveal cancer treatments in unfit cancer patients Journal of Clinical Oncology, 2014, 32, 9551-9551.	1.6	0
60	Association of sunitinib exposure with toxicity outcome in a real-life population of elderly patients with cancer Journal of Clinical Oncology, 2014, 32, e20523-e20523.	1.6	0
61	Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. British Journal of Cancer, 2013, 108, 1034-1041.	6.4	204
62	Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Targeted Oncology, 2011, 6, 253-258.	3.6	117
63	A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. Therapeutics and Clinical Risk Management, 0, Volume 18, 683-698.	2.0	2